Keith B Nolop
Overview
Explore the profile of Keith B Nolop including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
2114
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kopetz S, Desai J, Chan E, Hecht J, ODwyer P, Maru D, et al.
J Clin Oncol
. 2015 Oct;
33(34):4032-8.
PMID: 26460303
Purpose: BRAF V600E mutation is seen in 5% to 8% of patients with metastatic colorectal cancer (CRC) and is associated with poor prognosis. Vemurafenib, an oral BRAF V600 inhibitor, has...
2.
Butowski N, Colman H, de Groot J, Omuro A, Nayak L, Wen P, et al.
Neuro Oncol
. 2015 Oct;
18(4):557-64.
PMID: 26449250
Background: The colony stimulating factor 1 receptor (CSF1R) ligands, CSF1 and interleukin-34, and the KIT ligand, stem cell factor, are expressed in glioblastoma (GB). Microglia, macrophages, blood vessels, and tumor...
3.
Puzanov I, Amaravadi R, McArthur G, Flaherty K, Chapman P, Sosman J, et al.
Eur J Cancer
. 2015 May;
51(11):1435-43.
PMID: 25980594
Introduction: Vemurafenib induces tumour regression in most patients with BRAF(V600E)-mutant melanoma; eventually, most experience progressive disease (PD). Long-term follow-up of patients with BRAF(V600E) melanoma treated in the phase 1 vemurafenib...
4.
Lacouture M, Duvic M, Hauschild A, Prieto V, Robert C, Schadendorf D, et al.
Oncologist
. 2013 Mar;
18(3):314-22.
PMID: 23457002
Background: Vemurafenib has been approved for the treatment of patients with advanced BRAF(V600E)-mutant melanoma. This report by the Vemurafenib Dermatology Working Group presents the characteristics of dermatologic adverse events (AEs)...
5.
Sosman J, Kim K, Schuchter L, Gonzalez R, Pavlick A, Weber J, et al.
N Engl J Med
. 2012 Feb;
366(8):707-14.
PMID: 22356324
Background: Approximately 50% of melanomas harbor activating (V600) mutations in the serine-threonine protein kinase B-RAF (BRAF). The oral BRAF inhibitor vemurafenib (PLX4032) frequently produced tumor regressions in patients with BRAF...
6.
Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, et al.
N Engl J Med
. 2012 Jan;
366(3):207-15.
PMID: 22256804
Background: Cutaneous squamous-cell carcinomas and keratoacanthomas are common findings in patients treated with BRAF inhibitors. Methods: We performed a molecular analysis to identify oncogenic mutations (HRAS, KRAS, NRAS, CDKN2A, and...